RFA
EDIT icon

Resurgent Financial Advisors’s Editas Medicine EDIT Stock Holding History

Resurgent Financial Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,275
Closed -$20.2K – 527
2022
Q4 		$20.2K Buy
+2,275
New +$25K 0.01% 624

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Resurgent Financial Advisors's EDIT Position: Q1 2023 in Review

Resurgent Financial Advisors sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 2,275 shares — an estimated $20.2K sold.

Resurgent Financial Advisors first reported a position in EDIT in Q4 2022 and held it in 1 quarter. The position peaked at $20.2K in Q4 2022. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

  • Resurgent Financial Advisors reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
  • Resurgent Financial Advisors sold 2,275 Editas Medicine shares in Q1 2023, an estimated $20.2K.
  • Resurgent Financial Advisors first reported a position in Editas Medicine in Q4 2022 and held it in 1 quarter.
  • Resurgent Financial Advisors's Editas Medicine position peaked at $20.2K in Q4 2022.
  • 234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on Resurgent Financial Advisors's 13F filing for Q1 2023, filed 15 May 2023.